News

MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea

SHOW RELEASE

MediGene AG reports on first quarter of 2010:total revenue increased - cost constant

SHOW RELEASE

MediGene publishes first, preliminary results obtained in a phase II clinical trial of EndoTAGTM-1 for the treatment of triple receptor-negative breast cancer

SHOW RELEASE

New CFO Arnd Christ to take up position at MediGene in April

SHOW RELEASE

MediGene AG divests Oncolytic Herpes Simplex Viruses (oHSV) program to Catherex, Inc.

SHOW RELEASE

MediGene Signs Agreement with Meditrina for the Commercialization of Veregen® in Greece and Cyprus

SHOW RELEASE

MediGene appoints Arnd Christ as Chief Financial Officeras Successor to Dr. Thomas Klaue

SHOW RELEASE

MediGene AG Reports Financial Results for the 2009 Fiscal Year

SHOW RELEASE

MediGene's Veregen® launched by Solvay in Germany

SHOW RELEASE

MediGene and Teva sign agreement to commercialize Veregen(TM) in Israel

SHOW RELEASE